Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 1.00 |
| ▸ | SYK | P43405 | 14/20 | 0.72 |
| ▸ | AURKA | O14965 | 6/20 | 0.70 |
| ▸ | ITK | Q08881 | 2/20 | 0.68 |
| ▸ | PLK4 | O00444 | 1/20 | 0.68 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.68 |
| ▸ | JAK2 | O60674 | 1/20 | 0.68 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.68 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.68 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.68 |
| ▸ | INSR | P06213 | 1/20 | 0.68 |
| ▸ | LCK | P06239 | 1/20 | 0.68 |
| ▸ | FYN | P06241 | 1/20 | 0.68 |
| ▸ | CDK1 | P06493 | 1/20 | 0.68 |
| ▸ | FES | P07332 | 1/20 | 0.68 |
| ▸ | CSF1R | P07333 | 1/20 | 0.68 |
| ▸ | LYN | P07948 | 1/20 | 0.68 |
| ▸ | IGF1R | P08069 | 1/20 | 0.68 |
| ▸ | ROS1 | P08922 | 1/20 | 0.68 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31294266 | 0.84 | SYK (1.00) | KDRSYKAURKAITKPLK4 | |
| SCHEMBL656171 | 0.84 | SYK (1.00) | KDRSYKAURKAITKPLK4 | |
| R-112 SCHEMBL655935 | 0.82 | SYK (1.00) | KDRSYKAURKAMAPK8AURKB | |
| SCHEMBL656621 | 0.82 | SYK (0.72) | KDRSYKAURKAITKPLK4 | |
| R-112 SCHEMBL31294216 | 0.82 | SYK (1.00) | KDRSYKAURKAMAPK8AURKB | |
| SCHEMBL4935602 | 0.82 | SYK (0.97) | KDRSYKAURKAITKPLK4 | |
| Hydrochloric Acid SCHEMBL653397 | 0.82 | SYK (0.97) | KDRSYKAURKAITKPLK4 | |
| SCHEMBL655523 | 0.82 | SYK (1.00) | KDRSYKAURKAITKPLK4 | |
| R-112 SCHEMBL29360016 | 0.82 | SYK (1.00) | KDRSYKAURKAMAPK8AURKB | |
| SCHEMBL656931 | 0.82 | AURKA (1.00) | KDRSYKAURKAITKPLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 223 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150005297-A1 | 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2015-01-01 | — | — | US | claimed |
| US-8835430-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2014-09-16 | — | — | US | claimed |
| US-20140031350-A1 | 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2014-01-30 | — | — | US | claimed |
| US-8188276-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | claimed |
| EP-1471915-B1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2011-09-14 | — | — | EP | claimed |
| JP-4658477-B2 | — | — | 2011-03-23 | — | — | JP | claimed |
| US-20080039622-A1 | Inhibiting the immunoglobulin (Ig) IgE and/or IgG receptor using R940343, N4-[(2,2-Difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine; treating allergic and inflammatory diseases; syk kinase inhibitors | RIGEL PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | claimed |
| US-20070293524-A1 | Salts, hydrates, solvatesand/or N-oxides; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors; inhibiting an Fc receptor signal transduction cascade | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | claimed |
| US-20070293520-A1 | One amine is substituted with a fused heterocyclic ring and the other with a fused heterocyclic ring or phenyl ring, e.g., N2,N4-Bis(3,4-ethylenedioxyphenyl)-5-cyano-2,4-pyrimidinediamine; inhibit IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators such as histamine | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | claimed |
| US-20070293523-A1 | inhibitors of immunoglobulin E or G receptor signaling cascades; Syk kinase inhibitors; use as antiallergic, antiinflammatory agents | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | claimed |
| US-20070293522-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | claimed |
| US-20070293521-A1 | inhibitors of immunoglobulin E or G receptor signaling cascades; Syk kinase inhibitors; use as antiallergic, antiinflammatory agents | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | claimed |
| US-20070225321-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | US | claimed |
| US-20060058292-A1 | N4-[2,2-difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine; inhibit the immunoglobulins IgE or IgG receptor signaling cascades in mast, basophil cells; antiallergen, antiinflammatory agent; asthma, osteoarthritis | MIDCAP FINANCIAL TRUST | 2006-03-16 | — | — | US | claimed |
| EP-1471915-A4 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2006-02-15 | — | — | EP | claimed |
| JP-2005516046-A | — | — | 2005-06-02 | — | — | JP | claimed |
| EP-1471915-A2 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2004-11-03 | — | — | EP | claimed |
| US-20040029902-A1 | Antiinflamamtory agents | MIDCAP FINANCIAL TRUST | 2004-02-12 | — | — | US | claimed |
| WO-2003063794-A2 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2003-08-07 | — | — | WO | claimed |
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-10828301-B2 | 2,4-pyrimidinediamine compounds and their uses | Rigel Pharmceuticals, Inc. (US) | 2020-11-10 | — | — | US | disclosed |
| US-10709703-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10709703-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10682350-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20200085820-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2020-03-19 | — | — | US | disclosed |
| US-20190255047-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2019-08-22 | — | — | US | disclosed |
| US-10369148-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-10314840-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-9913842-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2018-03-13 | — | — | US | disclosed |
| US-9913842-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2018-03-13 | — | — | US | disclosed |
| US-20170246167-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170246167-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170246167-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170151239-A1 | 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2017-06-01 | — | — | US | disclosed |
| US-20170151239-A1 | 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2017-06-01 | — | — | US | disclosed |
| US-20170151239-A1 | 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2017-06-01 | — | — | US | disclosed |
| US-20170081290-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2017-03-23 | — | — | US | disclosed |
| US-20170081290-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2017-03-23 | — | — | US | disclosed |
| US-20170081290-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2017-03-23 | — | — | US | disclosed |
| US-9586908-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586908-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586908-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9540334-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540334-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540334-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9499493-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9499493-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9499493-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9416112-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-9416112-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-9416112-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-9346765-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-9346765-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-9346765-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20160009661-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2016-01-14 | — | — | US | disclosed |
| US-20160009661-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2016-01-14 | — | — | US | disclosed |
| US-20160009661-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2016-01-14 | — | — | US | disclosed |
| US-20160009660-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2016-01-14 | — | — | US | disclosed |
| US-20160009660-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2016-01-14 | — | — | US | disclosed |
| US-20160009660-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2016-01-14 | — | — | US | disclosed |
| US-20150329532-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150329532-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150329532-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-9162989-B2 | 2,4-Pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9162989-B2 | 2,4-Pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9162989-B2 | 2,4-Pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20150266828-A1 | 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150266828-A1 | 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150266828-A1 | 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2015-09-24 | — | — | US | disclosed |
| US-9133133-B2 | 2,4-pyridinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133133-B2 | 2,4-pyridinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133133-B2 | 2,4-pyridinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20150158823-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-20150158823-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-20150158823-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-9040550-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040550-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040550-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20150126504-A1 | 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150126504-A1 | 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150126504-A1 | 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-9018204-B1 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-9018204-B1 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-9018204-B1 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20150005297-A1 | 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20150005297-A1 | 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20150005297-A1 | 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20140330007-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140330007-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140330007-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140303154-A1 | 2,4-PYRIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140303154-A1 | 2,4-PYRIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140303154-A1 | 2,4-PYRIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-8853397-B2 | 2,4-pyrimidinediamine compounds and their uses | Rigel Pharmacuticals, Inc. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8853397-B2 | 2,4-pyrimidinediamine compounds and their uses | Rigel Pharmacuticals, Inc. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8853397-B2 | 2,4-pyrimidinediamine compounds and their uses | Rigel Pharmacuticals, Inc. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8835430-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835430-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835430-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-8822685-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822685-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822685-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8748597-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748597-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748597-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20140031350-A1 | 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031350-A1 | 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031350-A1 | 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20130324524-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| US-20130317216-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | MIDCAP FINANCIAL TRUST | 2013-11-28 | — | — | US | disclosed |
| US-8557806-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| EP-2281563-B1 | 2,4-Pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS INC (US) | 2013-09-18 | — | — | EP | disclosed |
| US-20130150349-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150349-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150349-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-8410266-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410266-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410266-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8334296-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-12-18 | — | — | US | disclosed |
| US-8334296-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-12-18 | — | — | US | disclosed |
| US-8334296-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-12-18 | — | — | US | disclosed |
| US-20120230984-A1 | Methods of Treating or Preventing Autoimmune Diseases With 2,4-Pyrimidinediamine Compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | US | disclosed |
| US-8188276-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188276-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188276-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-8158621-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-8148525-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148525-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148525-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20120045454-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. | 2012-02-23 | — | — | US | disclosed |
| US-20120045454-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. | 2012-02-23 | — | — | US | disclosed |
| US-20120045454-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. | 2012-02-23 | — | — | US | disclosed |
| EP-1471915-B1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2011-09-14 | — | — | EP | disclosed |
| EP-1471915-B1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20110144330-A1 | 2,4-Pyrimidinediamine Compounds and their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144330-A1 | 2,4-Pyrimidinediamine Compounds and their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144330-A1 | 2,4-Pyrimidinediamine Compounds and their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| EP-2316459-A1 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | Rigel Pharmaceuticals, Inc. (US) | 2011-05-04 | — | — | EP | disclosed |
| US-7906644-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-7906644-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-7906644-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| EP-2281563-A1 | 2,4-Pyrimidinediamine compounds and their uses | Rigel Pharmaceuticals, Inc. (US) | 2011-02-09 | — | — | EP | disclosed |
| EP-2281563-A1 | 2,4-Pyrimidinediamine compounds and their uses | Rigel Pharmaceuticals, Inc. (US) | 2011-02-09 | — | — | EP | disclosed |
| US-7825116-B2 | -(2-Aminopyrid-6-yl)-5-fluoro-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine; signal transduction cascade inhibitor; Fc receptors for immunoglobulins IgE and IgG antagonist; autoimmune diseases, antiinflammatory agent; rheumatoid arthritis, multiple sclerosis | RIGEL PHARMACEUTICALS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7820819-B2 | inhibitors of immunoglobulin E or G receptor signaling cascades; Syk kinase inhibitors; use as antiallergic, antiinflammatory agents | RIGEL PHARMACEUTICALS, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820819-B2 | inhibitors of immunoglobulin E or G receptor signaling cascades; Syk kinase inhibitors; use as antiallergic, antiinflammatory agents | RIGEL PHARMACEUTICALS, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820819-B2 | inhibitors of immunoglobulin E or G receptor signaling cascades; Syk kinase inhibitors; use as antiallergic, antiinflammatory agents | RIGEL PHARMACEUTICALS, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7812029-B1 | such as N4-[(2,2-Dimethyl-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine; Glomerulonephritis; rheumatoid arthritis; systemic lupus erythematosis; multiple sclerosis | RIGEL PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7803939-B2 | N2,N4-bis(4-ethoxyphenyl)-5-fluoro-2,4-pyrimidinediamine; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-7803939-B2 | N2,N4-bis(4-ethoxyphenyl)-5-fluoro-2,4-pyrimidinediamine; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-7803939-B2 | N2,N4-bis(4-ethoxyphenyl)-5-fluoro-2,4-pyrimidinediamine; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-20100197918-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100197918-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100197918-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100125069-A1 | Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds | RIGEL PHARMACEUTICALS INC. (US) | 2010-05-20 | — | — | US | disclosed |
| US-7655797-B2 | reacting a aminobenzoxazne or aminobenzothiazine or aminobenzodithiazine compounds wtih 2,4-dichloro-5-fluoropyrimidine to form 2,4-pyrimidinediamne compound; used to inhibit IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; antiinflammatory agent, antiallergen | RIGEL PHARMACEUTICALS, INC. (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655797-B2 | reacting a aminobenzoxazne or aminobenzothiazine or aminobenzodithiazine compounds wtih 2,4-dichloro-5-fluoropyrimidine to form 2,4-pyrimidinediamne compound; used to inhibit IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; antiinflammatory agent, antiallergen | RIGEL PHARMACEUTICALS, INC. (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655797-B2 | reacting a aminobenzoxazne or aminobenzothiazine or aminobenzodithiazine compounds wtih 2,4-dichloro-5-fluoropyrimidine to form 2,4-pyrimidinediamne compound; used to inhibit IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; antiinflammatory agent, antiallergen | RIGEL PHARMACEUTICALS, INC. (US) | 2010-02-02 | — | — | US | disclosed |
| US-7642351-B2 | 2,4-Pyrimidinediamine compounds and their uses | Rogel Pharmaceuticals, Inc. (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642351-B2 | 2,4-Pyrimidinediamine compounds and their uses | Rogel Pharmaceuticals, Inc. (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642351-B2 | 2,4-Pyrimidinediamine compounds and their uses | Rogel Pharmaceuticals, Inc. (US) | 2010-01-05 | — | — | US | disclosed |
| EP-2130541-A2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | Rigel Pharmaceuticals, Inc. (US) | 2009-12-09 | — | — | EP | disclosed |
| EP-1534286-B1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | RIGEL PHARMACEUTICALS INC (US) | 2009-12-09 | — | — | EP | disclosed |
| US-7589200-B2 | 5-Fluoro-4N-phenyl-4-pyrimidineamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589200-B2 | 5-Fluoro-4N-phenyl-4-pyrimidineamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589200-B2 | 5-Fluoro-4N-phenyl-4-pyrimidineamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-7557210-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557210-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557210-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-20090171086-A1 | inhibitors of immunoglobulin E or G receptor signaling cascades; Syk kinase inhibitors; use as antiallergic, antiinflammatory agents | RIGEL PHARMACEUTICALS, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090171086-A1 | inhibitors of immunoglobulin E or G receptor signaling cascades; Syk kinase inhibitors; use as antiallergic, antiinflammatory agents | RIGEL PHARMACEUTICALS, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090171086-A1 | inhibitors of immunoglobulin E or G receptor signaling cascades; Syk kinase inhibitors; use as antiallergic, antiinflammatory agents | RIGEL PHARMACEUTICALS, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090171085-A1 | N2,N4-bis(4-ethoxyphenyl)-5-fluoro-2,4-pyrimidinediamine; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors | RIGEL PHARMACEUTICALS, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090171085-A1 | N2,N4-bis(4-ethoxyphenyl)-5-fluoro-2,4-pyrimidinediamine; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors | RIGEL PHARMACEUTICALS, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090171085-A1 | N2,N4-bis(4-ethoxyphenyl)-5-fluoro-2,4-pyrimidinediamine; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors | RIGEL PHARMACEUTICALS, INC. | 2009-07-02 | — | — | US | disclosed |
| US-7550460-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20090156622-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. | 2009-06-18 | — | — | US | disclosed |
| US-20090156622-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. | 2009-06-18 | — | — | US | disclosed |
| US-20090156622-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. | 2009-06-18 | — | — | US | disclosed |
| US-7517886-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20090082567-A1 | reacting a aminobenzoxazne or aminobenzothiazine or aminobenzodithiazine compounds wtih 2,4-dichloro-5-fluoropyrimidine to form 2,4-pyrimidinediamne compound; used to inhibit IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; antiinflammatory agent, antiallergen | RIGEL PHARMACEUTICALS, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090082567-A1 | reacting a aminobenzoxazne or aminobenzothiazine or aminobenzodithiazine compounds wtih 2,4-dichloro-5-fluoropyrimidine to form 2,4-pyrimidinediamne compound; used to inhibit IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; antiinflammatory agent, antiallergen | RIGEL PHARMACEUTICALS, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090082567-A1 | reacting a aminobenzoxazne or aminobenzothiazine or aminobenzodithiazine compounds wtih 2,4-dichloro-5-fluoropyrimidine to form 2,4-pyrimidinediamne compound; used to inhibit IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; antiinflammatory agent, antiallergen | RIGEL PHARMACEUTICALS, INC. | 2009-03-26 | — | — | US | disclosed |
| US-7498435-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-7498435-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-7498435-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-7485724-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-7485724-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-7485724-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-7435814-B2 | 2,4-Pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7332484-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20080039622-A1 | Inhibiting the immunoglobulin (Ig) IgE and/or IgG receptor using R940343, N4-[(2,2-Difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine; treating allergic and inflammatory diseases; syk kinase inhibitors | RIGEL PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | disclosed |
| US-7329671-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-20070299095-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070293524-A1 | Salts, hydrates, solvatesand/or N-oxides; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors; inhibiting an Fc receptor signal transduction cascade | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293524-A1 | Salts, hydrates, solvatesand/or N-oxides; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors; inhibiting an Fc receptor signal transduction cascade | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293524-A1 | Salts, hydrates, solvatesand/or N-oxides; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors; inhibiting an Fc receptor signal transduction cascade | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293520-A1 | One amine is substituted with a fused heterocyclic ring and the other with a fused heterocyclic ring or phenyl ring, e.g., N2,N4-Bis(3,4-ethylenedioxyphenyl)-5-cyano-2,4-pyrimidinediamine; inhibit IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators such as histamine | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293520-A1 | One amine is substituted with a fused heterocyclic ring and the other with a fused heterocyclic ring or phenyl ring, e.g., N2,N4-Bis(3,4-ethylenedioxyphenyl)-5-cyano-2,4-pyrimidinediamine; inhibit IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators such as histamine | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293520-A1 | One amine is substituted with a fused heterocyclic ring and the other with a fused heterocyclic ring or phenyl ring, e.g., N2,N4-Bis(3,4-ethylenedioxyphenyl)-5-cyano-2,4-pyrimidinediamine; inhibit IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators such as histamine | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293523-A1 | inhibitors of immunoglobulin E or G receptor signaling cascades; Syk kinase inhibitors; use as antiallergic, antiinflammatory agents | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293523-A1 | inhibitors of immunoglobulin E or G receptor signaling cascades; Syk kinase inhibitors; use as antiallergic, antiinflammatory agents | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293523-A1 | inhibitors of immunoglobulin E or G receptor signaling cascades; Syk kinase inhibitors; use as antiallergic, antiinflammatory agents | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293522-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293522-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293522-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293521-A1 | inhibitors of immunoglobulin E or G receptor signaling cascades; Syk kinase inhibitors; use as antiallergic, antiinflammatory agents | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293521-A1 | inhibitors of immunoglobulin E or G receptor signaling cascades; Syk kinase inhibitors; use as antiallergic, antiinflammatory agents | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293521-A1 | inhibitors of immunoglobulin E or G receptor signaling cascades; Syk kinase inhibitors; use as antiallergic, antiinflammatory agents | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070225321-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070225321-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070225321-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070060603-A1 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | PFIZER INC. | 2007-03-15 | — | — | US | disclosed |
| US-20060135543-A1 | N4-(1,4-Benzoxazin-6-yl)-5-fluoro-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine or a salt, hydrate, solvate and/or N-oxide; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors | RIGEL PHARMACEUTICALS, INC. | 2006-06-22 | — | — | US | disclosed |
| US-7060827-B2 | Prevent immunoglobulin receptors signaling cascading; prevention diseases; drugs; antiinflammatory agents | RIGEL PHARMACEUTICALS, INC. (US) | 2006-06-13 | — | — | US | disclosed |
| US-20060058292-A1 | N4-[2,2-difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine; inhibit the immunoglobulins IgE or IgG receptor signaling cascades in mast, basophil cells; antiallergen, antiinflammatory agent; asthma, osteoarthritis | MIDCAP FINANCIAL TRUST | 2006-03-16 | — | — | US | disclosed |
| US-20060035916-A1 | N2,N4-bis(3-hydroxyphenyl)-5-fluoro-2,4-pyrimidinediamine or a salt, hydrate, solvate and/or N-oxide; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors | MIDCAP FINANCIAL TRUST | 2006-02-16 | — | — | US | disclosed |
| US-20060025410-A1 | N4-(1,4-Benzoxazin-6-yl)-5-fluoro-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine or a salt, hydrate, solvate and/or N-oxide; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors | MIDCAP FINANCIAL TRUST | 2006-02-02 | — | — | US | disclosed |
| US-20050209230-A1 | 2-leaving group-4-(substituted amino)-5-fluoropyrimidines such as 2-chloro-N4-(2-hydroxyphenyl)-5-fluoro-4-pyrimidineamine; chemical intermediates to compounds that inhibit the immunoglobulin (Ig) IgE and/or IgG receptor signaling cascades | MIDCAP FINANCIAL TRUST | 2005-09-22 | — | — | US | disclosed |
| EP-1534286-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | Rigel Pharmaceuticals, Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20050038243-A1 | Prevent immunoglobulin receptors signaling cascading; prevention diseases; drugs; antiinflammatory agents | MIDCAP FINANCIAL TRUST | 2005-02-17 | — | — | US | disclosed |
| WO-2004014382-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | RIGEL PHARMACEUTICALS (US) | 2004-02-19 | — | — | WO | disclosed |
| US-20040029902-A1 | Antiinflamamtory agents | MIDCAP FINANCIAL TRUST | 2004-02-12 | — | — | US | disclosed |
| US-20040029902-A1 | Antiinflamamtory agents | MIDCAP FINANCIAL TRUST | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (49 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120045454-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | KDR 537/4885SYK 54/4885AURKA 997/4885 |
| US-20140303154-A1 | 2,4-PYRIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | KDR 683/4885SYK 38/4885AURKA 1178/4885 |
| US-20060058292-A1 | N4-[2,2-difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine; inhibit the immunoglobulins IgE or IgG receptor signaling cascades in mast, basophil cells; antiallergen, antiinflammatory agent; asthma, osteoarthritis | FCER2, FCGR1A, HRH4 | KDR 547/4885SYK 36/4885AURKA 533/4885 |
| US-20150005297-A1 | 2,4-Pyrimidinediamine Compounds and Their Uses | FCER2, FCGR1A, FCGR2A | KDR 537/4885SYK 54/4885AURKA 997/4885 |
| US-20100197918-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | KDR 537/4885SYK 54/4885AURKA 997/4885 |
| US-20130150349-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | KDR 537/4885SYK 54/4885AURKA 997/4885 |
| US-20060035916-A1 | N2,N4-bis(3-hydroxyphenyl)-5-fluoro-2,4-pyrimidinediamine or a salt, hydrate, solvate and/or N-oxide; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors | SYK, FCER2, FCGR1A | KDR 292/4885SYK 1/4885AURKA 928/4885 |
| US-20090156622-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | KDR 537/4885SYK 54/4885AURKA 997/4885 |
| US-20070225321-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | KDR 537/4885SYK 54/4885AURKA 997/4885 |
| US-20040029902-A1 | Antiinflamamtory agents | FCER2, FCGR1A, HNMT | KDR 2425/4885SYK 251/4885AURKA 1221/4885 |
| US-20170246167-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | KDR 537/4885SYK 54/4885AURKA 997/4885 |
| US-20200085820-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | KDR 537/4885SYK 54/4885AURKA 997/4885 |
| US-20130317216-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | KDR 537/4885SYK 54/4885AURKA 997/4885 |
| US-20080039622-A1 | Inhibiting the immunoglobulin (Ig) IgE and/or IgG receptor using R940343, N4-[(2,2-Difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine; treating allergic and inflammatory diseases; syk kinase inhibitors | FCER2, FCGR1A, FCGR2A | KDR 155/4885SYK 4/4885AURKA 240/4885 |
| US-10682350-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | KDR 537/4885SYK 54/4885AURKA 997/4885 |
| US-20150126504-A1 | 2,4-Pyrimidinediamine Compounds and Their Uses | FCER2, FCGR1A, FCGR2A | KDR 537/4885SYK 54/4885AURKA 997/4885 |
| US-20100125069-A1 | Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds | SSB, TYMS, TPMT | KDR 3744/4885SYK 2199/4885AURKA 4287/4885 |
| US-20110144330-A1 | 2,4-Pyrimidinediamine Compounds and their Uses | FCER2, FCGR1A, FCGR2A | KDR 537/4885SYK 54/4885AURKA 997/4885 |
| US-20160009660-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | KDR 537/4885SYK 54/4885AURKA 997/4885 |
| US-10709703-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | KDR 537/4885SYK 54/4885AURKA 997/4885 |
| US-20070293523-A1 | inhibitors of immunoglobulin E or G receptor signaling cascades; Syk kinase inhibitors; use as antiallergic, antiinflammatory agents | FCER2, SYK, FCGR1A | KDR 426/4885SYK 2/4885AURKA 962/4885 |
| US-20140330007-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | KDR 537/4885SYK 54/4885AURKA 997/4885 |
| US-20090171085-A1 | N2,N4-bis(4-ethoxyphenyl)-5-fluoro-2,4-pyrimidinediamine; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors | FCER2, FCGR1A, SYK | KDR 220/4885SYK 3/4885AURKA 542/4885 |
| US-10314840-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | KDR 537/4885SYK 54/4885AURKA 997/4885 |
| US-10369148-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | KDR 537/4885SYK 54/4885AURKA 997/4885 |
| US-20060025410-A1 | N4-(1,4-Benzoxazin-6-yl)-5-fluoro-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine or a salt, hydrate, solvate and/or N-oxide; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors | SYK, FCER2, FCGR1A | KDR 393/4885SYK 1/4885AURKA 288/4885 |
| US-20070060603-A1 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | SSB, TYMS, TPMT | KDR 3744/4885SYK 2199/4885AURKA 4287/4885 |
| US-20160009661-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | KDR 537/4885SYK 54/4885AURKA 997/4885 |
| US-20050209230-A1 | 2-leaving group-4-(substituted amino)-5-fluoropyrimidines such as 2-chloro-N4-(2-hydroxyphenyl)-5-fluoro-4-pyrimidineamine; chemical intermediates to compounds that inhibit the immunoglobulin (Ig) IgE and/or IgG receptor signaling cascades | FCER2, FCGR1A, FCGR2A | KDR 220/4885SYK 42/4885AURKA 1583/4885 |
| US-20050038243-A1 | Prevent immunoglobulin receptors signaling cascading; prevention diseases; drugs; antiinflammatory agents | FCER2, FCGR1A, FCGR2A | KDR 436/4885SYK 83/4885AURKA 3432/4885 |
| US-20070293522-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | KDR 537/4885SYK 54/4885AURKA 997/4885 |
| US-20140031350-A1 | 2,4-Pyrimidinediamine Compounds and Their Uses | FCER2, FCGR1A, FCGR2A | KDR 537/4885SYK 54/4885AURKA 997/4885 |
| US-20170151239-A1 | 2,4-Pyrimidinediamine Compounds and Their Uses | FCER2, FCGR1A, FCGR2A | KDR 537/4885SYK 54/4885AURKA 997/4885 |
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | KDR 537/4885SYK 54/4885AURKA 997/4885 |
| US-20190255047-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | KDR 537/4885SYK 54/4885AURKA 997/4885 |
| US-20150329532-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | KDR 537/4885SYK 54/4885AURKA 997/4885 |
| US-20070299095-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | SSB, TYMS, TPMT | KDR 3744/4885SYK 2199/4885AURKA 4287/4885 |
| US-10828301-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | KDR 537/4885SYK 54/4885AURKA 997/4885 |
| US-20170081290-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | KDR 537/4885SYK 54/4885AURKA 997/4885 |
| US-20130324524-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | KDR 537/4885SYK 54/4885AURKA 997/4885 |
| US-20070293520-A1 | One amine is substituted with a fused heterocyclic ring and the other with a fused heterocyclic ring or phenyl ring, e.g., N2,N4-Bis(3,4-ethylenedioxyphenyl)-5-cyano-2,4-pyrimidinediamine; inhibit IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators such as histamine | HRH4, FCER2, HRH2 | KDR 265/4885SYK 78/4885AURKA 581/4885 |
| US-20070293521-A1 | inhibitors of immunoglobulin E or G receptor signaling cascades; Syk kinase inhibitors; use as antiallergic, antiinflammatory agents | FCER2, SYK, FCGR1A | KDR 426/4885SYK 2/4885AURKA 962/4885 |
| US-20070293524-A1 | Salts, hydrates, solvatesand/or N-oxides; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors; inhibiting an Fc receptor signal transduction cascade | SYK, FCER2, FCGR1A | KDR 310/4885SYK 1/4885AURKA 485/4885 |
| US-20060135543-A1 | N4-(1,4-Benzoxazin-6-yl)-5-fluoro-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine or a salt, hydrate, solvate and/or N-oxide; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors | SYK, FCER2, FCGR1A | KDR 393/4885SYK 1/4885AURKA 288/4885 |
| US-20150266828-A1 | 2,4-Pyrimidinediamine Compounds and Their Uses | FCER2, FCGR1A, FCGR2A | KDR 537/4885SYK 54/4885AURKA 997/4885 |
| US-20090082567-A1 | reacting a aminobenzoxazne or aminobenzothiazine or aminobenzodithiazine compounds wtih 2,4-dichloro-5-fluoropyrimidine to form 2,4-pyrimidinediamne compound; used to inhibit IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; antiinflammatory agent, antiallergen | HRH2, HRH1, FCER2 | KDR 641/4885SYK 71/4885AURKA 1292/4885 |
| US-20120230984-A1 | Methods of Treating or Preventing Autoimmune Diseases With 2,4-Pyrimidinediamine Compounds | SSB, TYMS, TPMT | KDR 3744/4885SYK 2199/4885AURKA 4287/4885 |
| US-20090171086-A1 | inhibitors of immunoglobulin E or G receptor signaling cascades; Syk kinase inhibitors; use as antiallergic, antiinflammatory agents | FCER2, SYK, FCGR1A | KDR 426/4885SYK 2/4885AURKA 962/4885 |
| US-20150158823-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | KDR 537/4885SYK 54/4885AURKA 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.